

Datasheet for 200-502-J35

AKT2 FITC Antibody**Overview**

Description:	Anti-AKT2 (RAT) Fluorescein Conjugated Monoclonal Antibody - 200-502-J35
Item No.:	200-502-J35
Size:	50 µg
Reactivity:	Human
Host Species:	Rat

Product Details

Background:	AKT is a component of the PI-3 kinase pathway and is activated by phosphorylation at Ser 473 and Thr 308. AKT is a cytoplasmic protein also known as AKT1, Protein Kinase B (PKB) and rac (related to A and C kinases). AKT is a key regulator of many signal transduction pathways. AKT Exhibits tight control over cell proliferation and cell viability. Overexpression or inappropriate activation of AKT is noted in many types of cancer. AKT mediates many of the downstream events of PI 3-kinase (a lipid kinase activated by growth factors, cytokines and insulin). PI 3-kinase recruits AKT to the membrane, where it is activated by PDK1 phosphorylation. Once phosphorylated, AKT dissociates from the membrane and phosphorylates targets in the cytoplasm and the cell nucleus. AKT has two main roles: (i) inhibition of apoptosis; (ii) promotion of proliferation. Anti-AKT2 (RAT) PE conjugated Monoclonal Antibody is ideal for investigators involved in Cell Signaling, Cancer, Neuroscience, Signal Transduction research.
Synonyms:	rat anti-Anti-AKT2 FITC Conjugation, Fluorescein Conjugated rat anti-Anti-AKT2, AKT 2 antibody, AKT-2, PKB antibody, PKB beta antibody, PKBBETA antibody, PRKBB antibody, Protein kinase Akt 2 antibody, Protein kinase B beta antibody, RAC-beta serine/threonine-protein kinase, RAC-PK-beta
Host Species:	Rat
Conjugate:	Fluorescein (FITC)
Clonality:	Monoclonal
Clone ID:	11F6.B2
Format:	IgG2a
F/P Ratio:	1-2

Target Details

Gene Name:	AKT2
Reactivity:	Human
Immunogen Type:	Conjugated Peptide
Immunogen:	Anti-AKT2 Antibody was produced in rat by repeated immunizations with a synthetic peptide corresponding to internal residues of human AKT2 protein.
Purity/Specificity:	Anti-AKT2 antibody is directed against human AKT2. The antibody detects both unphosphorylated and phosphorylated forms of the protein. Anti-AKT2 was purified from concentrated tissue culture supernate by Protein G chromatography. Cross reactivity with AKT2 from other species has not been determined, however, the sequence of the immunogen shows 88% identity to mouse and 90% identity with rat, therefore, cross reactivity is expected.
Relevant Links:	• UniProtKB - P31751 • NCBI - NP_001617.1 • GenelD - 208

Application Details

Application Note:	Anti-AKT2 FITC Antibody is suitable for Flow Cytometry, ELISA, immunohistochemistry, and western blotting. Expect a band approximately 56 kDa in size corresponding to AKT2 protein by western blotting in the appropriate cell lysate or extract. This monoclonal antibody reacts with human AKT. Specific conditions for reactivity should be optimized by the end user. For immunohistochemistry we recommend the use of fresh frozen tissues. Attempts at staining paraffin-embedded formalin fixed tissues were negative. No pre-treatment of sample is required.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	User Optimized
FC:	User Optimized
IF:	User Optimized
IHC:	User Optimized
WB:	User Optimized


Formulation

Physical State:	Lyophilized
Concentration:	1.0 mg/mL by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.5 M Sodium Chloride, pH 7.2
Preservative:	0.01% (w/v) Sodium Azide
Stabilizer:	10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free
Reconstitution Volume:	50µL
Reconstitution Buffer:	Restore with deionized water (or equivalent)

Shipping & Handling


Shipping Condition:	Wet Ice
Storage Condition:	Store vial at 4° C prior to restoration. Restore with deionized water (or equivalent). For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration:	Expiration date is one (1) year from date of receipt.

Images




ELISA

ELISA of Rat Monoclonal anti-AKT2 antibody. Antigen: GST AKT1, GST AKT2, GST AKT3. Coating amount: starting from 50 ng/well. Primary antibody: Rat monoclonal anti-AKT2 antibody at 100 ng/well. Dilution series: 2-fold. Mid-point concentration: 3 ng/mL Rat monoclonal anti-AKT2 antibody. Secondary antibody: Peroxidase rat secondary antibody at 1:10,000. Substrate: TMB (p/n TMBE-0100).



Western Blot

Western Blot of Rat Anti-AKT2 antibody. Lane 1: LnCap lysate Lane 2: Jurkat lysate. Lane 3: MDA-MB 468 lysate. Load: 5 µg per lane. Primary antibody: AKT2 unconjugated antibody at 1:1000 for overnight at 4°C. Secondary antibody: Rat secondary antibody at 1:20,000 for 45 min at RT. Block: 5% BLOTTO overnight at 4°C. Predicted/Observed size: 56 kDa for AKT2.



Western Blot

Western Blot of Rat monoclonal anti-AKT2 antibody. Lane 1: GST-AKT1. Lane 2: GST-AKT2. Lane 3: GST-AKT3. Load: 50 ng per lane. Primary antibody: anti-AKT2 unconjugated antibody at 1:1000 for overnight at 4°C. Secondary antibody: Goat secondary antibody anti rat at 1:40,000 for 45 min at RT. Block: 5% BLOTTO overnight at 4°C. Predicted/Observed size: 85 kDa for GST-AKT2.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.